Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Each disclosed tie as a share of both companies’ annual revenue. The bigger share is the side that would feel it if the relationship ended.
| Partner | % of their revenue | % of KYMR revenue | Skew |
|---|---|---|---|
| GILDGilead Sciences, Inc. | 0.02% | 14.30% | 751× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Collaboration revenues were $39.2 million for the year ended December 31, 2025, of which $33.6 million and $5.6 million were attributable to our collaboration agreements with Sanofi and Gilead, respectively.”
$6M relationship751× more of KYMR’s book than GILD’s
basisKYMR fy2025 · closed 2025-12 $39MGILD fy2025 · closed 2025-12 $29.4B
FILING10-K0001193125-26-073395cik 0001815442
“In October 2021, we entered into a sales agreement, or Cowen Sales Agreement, with Cowen, pursuant to which we were able to offer and sell shares of our common stock having aggregate gross proceeds of up to $250.0 million from time to time in "at-the-market" offerings through Cowen, as our sales agent.”
FILING10-K0000950170-25-028355cik 0001815442
“On October 31, 2024, we entered into an Open Market Sale Agreement SM , or Jefferies Sales Agreement, with Jefferies LLC, or Jefferies, pursuant to which we may offer and sell shares of our common stock having aggregate gross proceeds of up to $300.0 million from time to time in "at-the-market" offerings through Jefferies, as our sales agent.”
FILING10-K0000950170-25-028355cik 0001815442
“In consideration for the exclusive licenses granted to Sanofi under the Sanofi Agreement, Sanofi paid to us an upfront payment of $150.0 million.”
FILING10-K0000950170-25-028355cik 0001815442
“Vertex provided us with a non-refundable upfront payment of $50.0 million and purchased 3,059,695 shares of our Series B-1 Convertible Preferred Stock at $6.54 a share, pursuant to a separate, but simultaneously executed Share Purchase Agreement.”
FILING10-K0000950170-25-028355cik 0001815442
“Kymera (2020): agreement to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases;”
FILING20-F0001628280-26-008403cik 0001121404disclosed by SNY
Watchlist prices, news filtered to it, and its next report on your desk.
Prev close 113.09 · gapped above the open, then crossed back over prior close. High/low 115.50 at 8:00 am ET, 110.59 at 11:00 am ET.
Kymera Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Kymera Therapeutics, Inc. has 2 disclosed suppliers and 4 disclosed customers. Each one is named in an SEC filing, either Kymera Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
KYMR (Kymera Therapeutics, Inc.) has 2 disclosed suppliers and 4 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: SNY −2.03%, in industrials & materials.